A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Clinical trial NCT06601517 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06601517
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Adult Subject Overweight Subject

Start date: 2024-10-01
Primary completion: 2025-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.